2. Academic Validation
  3. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway

Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway

  • Int Immunopharmacol. 2023 Feb 2;116:109753. doi: 10.1016/j.intimp.2023.109753.
Jiarui Zheng 1,  Yao Lu 1,  Jun Xiao 1,  Yongjuan Duan 2,  Suyu Zong 2,  Xiaoli Chen 2,  Tianyuan Hu 2,  Long Li 3,  Yingchi Zhang 4
Affiliations

Affiliations

  • 1 Tianjin Institute of Immunology, Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education and Department of Immunology, Tianjin Medical University, Tianjin 300070, China.
  • 2 State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300041, China.
  • 3 Tianjin Institute of Immunology, Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education and Department of Immunology, Tianjin Medical University, Tianjin 300070, China. Electronic address: [email protected].
  • 4 State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300041, China. Electronic address: [email protected].
PMID: 36738675 DOI: 10.1016/j.intimp.2023.109753
Abstract

Background: Natural killer (NK) cells are a subtype of lymphocytes with the ability to quickly and efficiently identify and eliminate tumor cells. In the presence of IL2, NK cells can divide rapidly but in limited numbers. According to previous studies, in vivo treatment with histone deacetylase (HDAC) inhibitors did not impair NK-cell function. This study aimed to investigate the effect of HDAC inhibitors on NK-cell proliferation and the underlying regulatory mechanism.

Methods: NK92 cells, primary NK (pNK) cells, and CD19-CAR-NK92 cells were treated with low concentrations of pan-HDACi Dacinostat (Dac) and Panobinostat (Pan) in the presence of IL2, and Cell Counting Kit-8 (CCK8), 5-ethynyl-2'-deoxyuridine (EdU), and flow cytometry assays were used to assess cell proliferation and Apoptosis. The expression of granzyme B was detected by immunofluorescence, and the expression of CD107a and NKG2D was determined by flow cytometry. The downstream regulatory genes were identified by RNA-seq, and the "JAK-STAT signaling pathway"- and "Cell cycle signaling pathway"-related genes were detected by real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis. The JAK2V617F mouse model was constructed to simulate the upregulation of the JAK2 signaling pathway in vivo, and the NK proliferation was evaluated by flow cytometry. A tumor-bearing nude mouse model was constructed to determine the anti-tumor efficacy of NK92 cells following Dac treatment.

Results: In the presence of IL2, the proliferation rate of NK92 cells, pNK cells, and CD19-CAR-NK92 cells treated with pan-HDACi Dac and Pan at low nanomolar doses was significantly increased, although cell function was unaffected. Low doses of Dac upregulated the JAK-STAT signaling pathway and enhance the cell cycle via that pathway. In addition, the in vivo experiment in nude mice showed that the capacity of Dac treated NK92 cells to eliminate tumor cells was unaffected.

Conclusion: Low nanomolar doses of Pan-HDACi enhanced IL2-induced NK cell proliferation without compromising the functioning of NK cells.

Keywords

Antitumor activity; HDAC inhibitor; IL2; NK cell; Proliferation.

Figures
Products